机构：[1]School of Traditional Chinese Medicine, Southern Medical University, Guangzhou 510515, Guangdong, China.[2]Department of Epidemiology, School of Public Health, Southern Medical University, Guangzhou 510515, Guangdong, China.[3]Guangdong Provincial Key Laboratory of Chinese Medicine Pharmaceutics, School of Traditional Chinese Medicine, Southern Medical University, Guangzhou 510515, Guangdong, China.[4]Department of pharmacy, Nanfang Hospital, Southern Medical University, Guangzhou 510515, Guangdong, China.[5]The Affiliated TCM Hospital of Guangzhou Medical University, Guangzhou 510130, Guangdong, China
Clear cell renal cell carcinoma (ccRCC) is a common urological malignancy with diverse histological types. This study aimed to detect neoantigens in ccRCC to develop mRNA vaccines and distinguish between ccRCC immunological subtypes for construction of an immune landscape to select patients suitable for vaccination. Using The Cancer Genome Atlas SpliceSeq database, The Cancer Genome Atlas, and the International Cancer Genome Consortium cohorts, we comprehensively analysed potential tumour antigens of ccRCC associated with aberrant alternative splicing, somatic mutation, nonsense-mediated mRNA decay factors, antigen-presenting cells, and overall survival. Immune subtypes (C1/C2) and nine immune gene modules of ccRCC were identified by consistency clustering and weighted correlation network analysis. The immune landscape as well as molecular and cellular characteristics of immunotypes were assessed. Rho-guanine nucleotide exchange factor 3 (ARHGEF3) was identified as a new ccRCC antigen for development of an mRNA vaccine. A higher tumour mutation burden, differential expression of immune checkpoints, and immunogenic cell death were observed in cases with the C2 immunotype. Cellular characteristics increased the complexity of the immune environment, and worse outcomes were observed in ccRCC cases with the C2 immunotype. We constructed the immune landscape for selecting patients with the C2 immunotype suitable for vaccination.
基金：
National Natural Science Foundation of China (81873332) and Innovation team project of Guangdong Province (2019KCXTD014) and Project of Administration of Traditional Chinese Medicine of Guangdong Province of China (20221258).
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2022]版：
大类|2 区医学
小类|3 区老年医学3 区细胞生物学
最新[2025]版：
无
第一作者：
第一作者机构：[1]School of Traditional Chinese Medicine, Southern Medical University, Guangzhou 510515, Guangdong, China.
共同第一作者：
通讯作者：
推荐引用方式(GB/T 7714)：
Zhu Daoqi,Yang Jiabin,Zhang Minyi,et al.Identification of neoantigens and immunological subtypes in clear cell renal cell carcinoma for mRNA vaccine development and patient selection[J].Aging.2023,15(11):5190-5214.doi:10.18632/aging.204798.
APA：
Zhu Daoqi,Yang Jiabin,Zhang Minyi,Han Zhongxiao,Shao Meng...&Xiao Wei.(2023).Identification of neoantigens and immunological subtypes in clear cell renal cell carcinoma for mRNA vaccine development and patient selection.Aging,15,(11)
MLA：
Zhu Daoqi,et al."Identification of neoantigens and immunological subtypes in clear cell renal cell carcinoma for mRNA vaccine development and patient selection".Aging 15..11(2023):5190-5214
